Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

BioNano Genomics (0A4K) Share Price & Analysis

13 Followers

0A4K Stock Chart & Stats

$5.25$0.00(0.00%)
At close: 4:30 PM GMT
$5$10$15$20Nov 4Nov 18Dec 2Dec 16Dec 30Jan 13Jan 28
Day’s Range
$5.25 - $5.25
52-Week Range
$5.25 - $5.25
Previous Close
$5.25
Volume
N/A
Average Volume (3M)
0
Market Cap
$15.38M
Enterprise Value
$16.58M
Total Cash (Recent Filing)
$4.36M
Total Debt (Recent Filing)
$6.54M
Price to Earnings (P/E)
―
Beta
0.66
Next Earnings
Mar 10, 2027 (Est.)
EPS Estimate
-0.39
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Recurring Consumables Growth

Strong consumables growth from existing customers indicates rising utilization of the installed OGM base, supporting a more recurring revenue mix. Greater sample throughput can deepen customer workflow integration and improve the platform’s long-term revenue durability.

Reimbursement And Clinical Adoption

Expanding reimbursement support can reduce a major barrier to clinical adoption by improving payment visibility for laboratories and physicians. Broad Medicare coverage would strengthen OGM’s commercial foundation and potentially encourage private insurers and new clinical sites to adopt the platform.

Improving Operating Economics

Higher gross margin combined with lower operating expenses shows progress toward better operating leverage, even before profitability is reached. If maintained as revenue scales, these improvements can reduce the funding burden and support management’s stated path toward EBITDA neutrality.

Bears Say

Persistent Cash Burn

Ongoing negative operating and free cash flow means the business is not yet self-funding its operations. Continued cash consumption can restrict investment flexibility and increase dependence on external capital unless revenue growth and expense control are sufficient to reach breakeven.

Deep Operating Losses

The gap between improved gross margin and deeply negative operating profitability shows that expenses still substantially exceed gross profit. Until this cost structure is reduced or revenue scales materially, earnings recovery remains uncertain and financial resources may continue to be depleted.

Software Revenue Pressure

Software revenue weakness creates a structural headwind because software can provide higher-margin, recurring economics around the platform. Management expects migration-related declines to be offset by deeper OGM adoption, but that replacement depends on successful customer conversion and utilization growth.

BioNano Genomics News

0A4K FAQ

What was BioNano Genomics’s price range in the past 12 months?
BioNano Genomics lowest share price was $5.25 and its highest was $5.25 in the past 12 months.
What is BioNano Genomics’s market cap?
BioNano Genomics’s market cap is $15.38M.
When is BioNano Genomics’s upcoming earnings report date?
BioNano Genomics’s next earnings report is estimated for Mar 10, 2027 (not yet confirmed), which is in 116 days.
How were BioNano Genomics’s earnings last quarter?
BioNano Genomics released its earnings results on Nov 10, 2026. The company reported -$0.45 earnings per share for the quarter.
Is BioNano Genomics overvalued?
According to Wall Street analysts BioNano Genomics’s price is currently Overvalued.
Does BioNano Genomics pay dividends?
BioNano Genomics does not currently pay dividends.
What is BioNano Genomics’s EPS estimate?
BioNano Genomics’s EPS estimate is -0.39.
How many shares outstanding does BioNano Genomics have?
BioNano Genomics has 13,979,584 shares outstanding.
What happened to BioNano Genomics’s price movement after its last earnings report?
BioNano Genomics reported an EPS of -$0.45 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioNano Genomics?
Hedge funds hold BioNano Genomics shares: the largest hedge-fund position in BioNano Genomics is 854,785,353 shares, and hedge funds decreased their holdings by 8.8K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology